Introduction: In this study, we investigated the effect of drug dose on the progression of retinal vascularization in eyes treated with different doses of intravitreal bevacizumab (IVB). Methods: The patient charts of 259 eyes of 142 patients who were administered 0.3125 mg or 0.625 mg IVB as primary therapy for type 1 retinopathy of prematurity (ROP) or aggressive ROP (A-ROP) were retrospectively evaluated. Eighty-four eyes of 42 infants met all study inclusion criteria and underwent further morphological evaluation. Eyes treated with 0.3125 mg and 0.625 mg bevacizumab were grouped as the low dose and standard dose groups, respectively. Horizontal disc diameter (DD), optic disc-to-fovea distance (FD), and the length of temporal retinal vascularization (LTRV) were measured on pretreatment photographs (PPs) and final fluorescein angiography (FA) images. LTRV, measured in pixels, was converted to DD and FD units and analyzed. All PPs and FA images were captured with 130° PanoCam Pro camera. The difference between final LTRV and pretreatment LTRV was defined as the difference of LTRV. The ratio of difference of LTRV to pretreatment LTRV was defined as the rate of increase of LTRV. Results: Of the 255 eyes, re-treatment rate before 55 weeks postmenstrual age (PMA) was 23% in the eyes treated with 0.3125 mg IVB and 19% in the eyes treated with 0.625 mg IVB (p = 0.362). Of the 42 infants included for further morphological evaluation, the median age at the time of treatment was 36 (35–38) weeks PMA, and the median age at the time of FA imaging was 66 (62–75) weeks PMA. While the difference of LTRV by unit of DD was higher in the low dose group (p = 0.017), this difference was similar between groups by unit of FD (p = 0.412). The ratio of the increase of the LTRV was similar between groups by units of DD and FD (p = 0.081, p = 0.390; respectively). The FD/DD ratio was 4.13 ± 0.49 and 3.26 ± 0.33 at the pretreatment and final sessions, respectively (p = 0.000). Conclusion: The ratio of FD to DD decreased significantly with increasing age. The additional treatment rate and progression of retinal vascularization by unit of FD were similar between the groups. The difference of LTRV by unit of DD was higher in the low dose group. The usage of dif-ferent formulas and methods may affect the evaluation of the progression of retinal vascularization.

1.
Hartnett
ME
.
Pathophysiology and mechanisms of severe retinopathy of prematurity
.
Ophthalmology
.
2015
;
122
(
1
):
200
10
. .
2.
Hartnett
ME
,
Penn
JS
.
Mechanisms and management of retinopathy of prematurity
.
N Engl J Med
.
2012
;
367
(
26
):
2515
26
. .
3.
Quinn
GE
.
Retinopathy of prematurity blindness worldwide: phenotypes in the third epidemic
.
Eye Brain
.
2016
;
8
:
31
. .
4.
Shah
PK
,
Narendran
V
,
Kalpana
N
.
Aggressive posterior retinopathy of prematurity in large preterm babies in South India
.
Arch Dis Child Fetal Neonatal Ed
.
2012
;
97
(
5
):
F371
5
. .
5.
Bas
AY
,
Demirel
N
,
Koc
E
,
Isik
DU
,
Hirfanoglu
İM
,
Tunc
T
.
Incidence, risk factors and severity of retinopathy of prematurity in Turkey (TR-ROP study): a prospective, multicentre study in 69 neonatal intensive care units
.
Br J Ophthalmol
.
2018
;
102
(
12
):
1711
6
.
6.
Erşan
HBA
,
Pinhan
D
,
Kavuncuoğlu
S
,
Sayın
N
,
Bayramoğlu
SE
,
Çetinkaya
M
.
The demographic and clinical characteristics of the patients treated for type 1 retinopathy of prematurity
.
İKSST Derg
.
2018
;
10
(
2
):
81
6
.
7.
Early Treatment for Retinopathy of Prematurity Cooperative Group
.
Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial
.
Arch Ophthalmol
.
2003
;
121
:
1684
94
. .
8.
Cryotherapy for Retinopathy of Prematurity Cooperative Group
.
Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results
.
Pediatrics
.
1988
;
81
(
5
):
697
706
.
9.
Travassos
A
,
Teixeira
S
,
Ferreira
P
,
Regadas
I
,
Travassos
AS
,
Esperancinha
FE
,
Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity
.
Ophthalmic Surg
.
2007
;
38
(
3
):
233
7
.
10.
Geloneck
MM
,
Chuang
AZ
,
Clark
WL
,
Hunt
MG
,
Norman
AA
,
Packwood
EA
,
Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial
.
JAMA Ophthalmol
.
2014
;
132
(
11
):
1327
33
.
11.
Mintz-Hittner
HA
,
Kennedy
KA
,
Chuang
AZ
.
Efficacy of intravitreal bevacizumab for stage 3 + retinopathy of prematurity
.
N Engl J Med
.
2011
;
364
(
7
):
603
15
. .
12.
Stone
J
,
Itin
A
,
Alon
T
,
Pe’Er
J
,
Gnessin
H
,
Chan-Ling
T
,
Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia
.
J Neurosci
.
1995
;
15
(
7
):
4738
47
.
13.
Wu
WC
,
Lien
R
,
Liao
PJ
,
Wang
NK
,
Chen
YP
,
Chao
AN
,
Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity
.
JAMA Ophthalmol
.
2015
;
133
(
4
):
391
7
.
14.
Haigh
JJ
.
Role of VEGF in organogenesis
.
Organogenesis
.
2008
;
4
(
4
):
247
56
. .
15.
Lorenz
B
,
Stieger
K
,
Jäger
M
,
Mais
C
,
Stieger
S
,
Andrassi-Darida
M
.
Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity
.
Retina
.
2017
;
37
(
1
):
97
111
.
16.
Wallace
DK
,
Kraker
RT
,
Freedman
SF
,
Crouch
ER
,
Hutchinson
AK
,
Bhatt
AR
,
Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study
.
JAMA Ophthalmol
.
2017
;
135
(
6
):
654
6
.
17.
Wallace
DK
,
Dean
TW
,
Hartnett
ME
,
Kong
L
,
Smith
LE
,
Hubbard
GB
,
A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments
.
Ophthalmology
.
2018
;
125
(
12
):
1961
6
.
18.
Wallace
DK
,
Kraker
RT
,
Freedman
SF
,
Crouch
ER
,
Bhatt
AR
,
Hartnett
ME
,
Short-term outcomes after very low-dose intravitreous Bevacizumab for retinopathy of prematurity
.
JAMA Ophthalmol
.
2020
;
138
(
6
):
698
701
.
19.
Akdogan
M
,
Cevik
SG
,
Sahin
O
.
The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity
.
Indian J Ophthalmol
.
2019
;
67
(
6
):
879
. .
20.
Hajrasouliha
AR
,
Garcia-Gonzales
JM
,
Shapiro
MJ
,
Yoon
H
,
Blair
MP
.
Reactivation of retinopathy of prematurity three years after treatment with bevacizumab
.
Ophthalmic Surg Lasers Imaging Retina
.
2017
;
48
(
3
):
255
9
. .
21.
Warren
CC
,
Young
JB
,
Goldberg
MR
,
Connor
TB
,
Kassem
IS
,
Costakos
DM
.
Findings in persistent retinopathy of prematurity
.
Ophthalmic Surg Lasers Imaging Retina
.
2018
;
49
(
7
):
497
503
. .
22.
Snyder
LL
,
Garcia-Gonzalez
JM
,
Shapiro
MJ
,
Blair
MP
.
Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab
.
Ophthalmic Surg Lasers Imaging Retina
.
2016
;
47
(
3
):
280
3
. .
23.
Mintz-Hittner
HA
,
Geloneck
MM
,
Chuang
AZ
.
Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy
.
Ophthalmology
.
2016
;
123
(
9
):
1845
55
. .
24.
Gonzalez
JMG
,
Snyder
L
,
Blair
M
,
Rohr
A
,
Shapiro
M
,
Greenwald
M
.
Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity
.
Retina
.
2018
;
38
(
4
):
764
72
.
25.
Wu
W-C
,
Shih
C-P
,
Lien
R
,
Wang
N-K
,
Chen
Y-P
,
Chao
A-N
,
Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity
.
Retina
.
2017
;
37
(
4
):
694
701
.
26.
Sato
T
,
Wada
K
,
Arahori
H
,
Kuno
N
,
Imoto
K
,
Iwahashi-Shima
C
,
Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity
.
Am J Ophthalmol
.
2012
;
153
(
2
):
327
.
27.
Blair
MP
,
Shapiro
MJ
,
Hartnett
ME
.
Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children
.
J AAPOS
.
2012
;
16
(
3
):
234
7
. .
28.
Ekinci
DY
,
Çelik
K
.
Comparison of the efficacy between intravitreal aflibercept and laser photocoagulation in the treatment of retinopathy of prematurity
.
J Pediatr Ophthalmol Strabismus
.
2020
;
57
(
1
):
54
60
. .
29.
Fielder
AR
,
Wallace
DK
,
Stahl
A
,
Reynolds
JD
,
Chiang
MF
,
Quinn
GE
.
Describing retinopathy of prematurity: current limitations and new challenges
.
Ophthalmology
.
2019
;
126
(
5
):
652
4
. .
30.
De Silva
DJ
,
Cocker
KD
,
Lau
G
,
Clay
ST
,
Fielder
AR
,
Moseley
MJ
.
Optic disk size and optic disk-to-fovea distance in preterm and full-term infants
.
Invest Ophthalmol Vis Sci
.
2006
;
47
(
11
):
4683
6
. .
31.
Knaapi
L
,
Lehtonen
T
,
Vesti
E
,
Leinonen
MT
.
Determining the size of retinal features in prematurely born children by fundus photography
.
Acta Ophthalmol
.
2015
;
93
(
4
):
339
41
. .
32.
Williams
TD
,
Wilkinson
JM
.
Position of the fovea centralis with respect to the optic nerve head
.
Optom Vis Sci
.
1992
;
69
(
5
):
369
77
. .
33.
Bennett
AG
,
Rudnicka
AR
,
Edgar
DF
.
Improvements on Littmann’s method of determining the size of retinal features by fundus photography
.
Graefes Arch Clin Exp Ophthalmol
.
1994
;
232
(
6
):
361
7
. .
34.
Bach
A
,
Villegas
VM
,
Gold
AS
,
Shi
W
,
Murray
TG
.
Axial length development in children
.
Int J Ophthalmol
.
2019
;
12
(
5
):
815
. .
35.
Ekinci
DY
,
Vural
AD
,
Bayramoglu
SE
,
Onur
IU
,
Hergunsel
GO
.
Assessment of vascular leakage and its development with FFA among patients treated with intravitreal anti-VEGF due to aggressive posterior ROP
.
Int Ophthalmol
.
2019
;
39
(
12
):
2697
705
. .
36.
Vural
A
,
Ekinci
DY
.
Comparison of vascular outgrowth rate and retinal vascular development border after intravitreal injection of aflibercept or bevacizumab to treat retinopathy of prematurity
.
Ophthalmologica
.
2020
;
243
(
2
):
86
93
.
37.
Mansukhani
SA
,
Hutchinson
AK
,
Neustein
R
,
Schertzer
J
,
Allen
JC
,
Hubbard
GB
.
Fluorescein angiography in retinopathy of prematurity: comparison of infants treated with bevacizumab to those with spontaneous regression
.
Ophthalmol Retina
.
2019
;
3
(
5
):
436
43
. .
38.
Patel
SN
,
Klufas
MA
,
Ryan
MC
,
Jonas
KE
,
Ostmo
S
,
Martinez-Castellanos
MA
,
Color fundus photography versus fluorescein angiography in identification of the macular center and zone in retinopathy of prematurity
.
Am J Ophthalmol
.
2015
;
159
(
5
):
950
7. e2
.
39.
Morin
J
,
Luu
TM
,
Superstein
R
,
Ospina
LH
,
Lefebvre
F
,
Simard
M-N
,
Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity
.
Pediatrics
.
2016
;
137
(
4
):
e20153218
.
40.
Tsai
CY
,
Yeh
PT
,
Tsao
PN
,
Chung
YE
,
Chang
YS
,
Lai
TT
.
Neurodevelopmental outcomes after bevacizumab treatment for retinopathy of prematurity: a meta-analysis
.
Ophthalmology
.
2021
;
128
(
6
):
877
88
. .
41.
Becker
S
,
Wang
H
,
Simmons
AB
,
Suwanmanee
T
,
Stoddard
GJ
,
Kafri
T
,
Targeted knockdown of overexpressed VEGFA or VEGF164 in Müller cells maintains retinal function by triggering different signaling mechanisms
.
Sci Rep
.
2018
;
8
(
1
):
1
13
.
42.
Simmons
AB
,
Bretz
CA
,
Wang
H
,
Kunz
E
,
Hajj
K
,
Kennedy
C
,
Gene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy
.
Angiogenesis
.
2018
;
21
(
4
):
751
64
.
43.
Hartnett
ME
.
Discovering mechanisms in the changing and diverse pathology of retinopathy of prematurity: the weisenfeld award lecture
.
Invest Ophthalmol Vis Sci
.
2019
;
60
(
5
):
1286
97
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.